5,408 Shares in Becton, Dickinson and Company $BDX Purchased by Spartan Wealth Advisory Services LLC

Spartan Wealth Advisory Services LLC purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 5,408 shares of the medical instruments supplier’s stock, valued at approximately $850,000.

Several other large investors have also recently added to or reduced their stakes in the company. Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the third quarter valued at approximately $25,000. Steph & Co. boosted its holdings in shares of Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 65 shares in the last quarter. SHP Wealth Management bought a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $26,000. Main Street Group LTD acquired a new stake in Becton, Dickinson and Company during the 1st quarter valued at $29,000. Finally, Prosperity Bancshares Inc acquired a new stake in Becton, Dickinson and Company during the 4th quarter valued at $29,000. 86.97% of the stock is owned by institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at $16,122,355.05. This represents a 2.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 5,188 shares of company stock valued at $765,120 in the last three months. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $158.14 on Monday. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $43.57 billion, a P/E ratio of 40.04, a PEG ratio of 11.19 and a beta of 0.21. The business has a 50-day moving average of $148.99 and a 200-day moving average of $166.18. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. The business had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. Becton, Dickinson and Company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the company posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 12.62 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were issued a $1.05 dividend. The ex-dividend date of this dividend was Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. Becton, Dickinson and Company’s payout ratio is 106.33%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on BDX shares. The Goldman Sachs Group reduced their price objective on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. Stifel Nicolaus cut their price target on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Wells Fargo & Company upped their price target on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a report on Tuesday, April 14th. Finally, Barclays raised their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $180.29.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.